Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome

Next Previous
Trial Profile

A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Telotristat etiprate (Primary)
  • Indications Malignant carcinoid syndrome
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms TELECAST
  • Sponsors Lexicon Pharmaceuticals

Most Recent Events

  • 28 Sep 2021 Results of pooled analysis of two phase III clinical TELESTAR and TELECAST trials assessing weight changes and nutritional metabolic disorder status, including cholesterol and albumin concentrations published in the Clinical Therapeutics
  • 16 Oct 2018 Brazil and Italy were the planned locations for this study.
  • 16 Oct 2018 According to an Ipsen media release, based on the positive results of the TELESTAR and TELECAST trials, the Health Canada approved XERMELO (telotristat ethyl) for the treatment of refractory carcinoid syndrome diarrhea, in combination with somatostatin analogue therapy, in patients inadequately controlled by SSA therapy alone.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top